TuHURA Biosciences draws another $650,000 on Parkview credit line

The draw and the facility

TuHURA Biosciences, Inc. received and borrowed an additional draw of $650,000 under its revolving credit facility on September 21, 2026, according to a Form 8-K dated September 24. The company expects to use the funds for general corporate purposes.

The facility comes from a Loan Agreement the company entered into on April 21, 2026 with Parkview Holdings One LLC, as lender. The revolving credit facility matures April 21, 2031, and its maximum loan availability is $50 million. The company filed the Loan Agreement as Exhibit 4.1 to an 8-K filed April 22, 2026.

The filing names no placement agent, financial advisor or counsel. It flags potential conflicts of interest arising from the Loan Agreement with an affiliate of the company's largest stockholder. Dan Dearborn, chief financial officer, signed the report.

The conditions on further draws

The 8-K says the company may be unable to meet the conditions for drawing funds, or to stay in compliance with the terms of the loan. It also says funds under the Loan Agreement may not be enough to fund operations and development programs as planned. The filing does not give the conditions for drawing funds or the covenants the company must meet.

The draw is small next to the company's spending in 2025.

What TuHURA is developing

TuHURA describes itself as a phase 3 clinical stage immuno-oncology company with three technologies. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company initiated a single randomized, placebo-controlled phase 3 registration trial in June 2025, testing IFx2.0 as an adjunctive therapy to Keytruda in first-line treatment of advanced or metastatic Merkel cell carcinoma, under the FDA's accelerated approval pathway.

Through its acquisition of Kineta, Inc. on June 30, 2025, TuHURA acquired the rights to TBS-2025, a VISTA-inhibiting monoclonal antibody formerly known as KVA1213. The company plans a phase 1b/2 trial of TBS-2025 in relapsed or refractory NPM1-mutated acute myeloid leukemia. The company also says it is developing bi-functional, bi-specific antibody-drug conjugates based on its Delta Opioid Receptor technology, aimed at myeloid derived suppressor cells.

Neither the 10-K nor the 8-K reports trial results for IFx2.0 or TBS-2025, so the efficacy of both is untested in these documents.

The company's history includes a reverse merger with Kintara Therapeutics, completed October 18, 2024, after which Kintara was renamed TuHURA Biosciences. The Kineta acquisition gave the former Kineta stockholders about 4 million shares of common stock.

The money

The 10-K shows no revenue in 2025 or 2024. Research and development expense rose to $20.5 million in 2025 from $13.3 million in 2024. The net loss was $30.1 million in 2025, against $21.7 million in 2024. Cash used in operations was $27.6 million in 2025, compared with $14.7 million in 2024.

Year-end cash and cash equivalents were $3.6 million for 2025, according to a 10-Q filed August 14, 2026, and $12.7 million for 2024. At June 30, 2026, cash and cash equivalents were $995,977, according to the 10-Q.

The company therefore had less than $1 million of cash at mid-2026, after a year in which it used $27.6 million in operations. The $650,000 draw adds to a cash position that is already very small.

What comes next

The filing gives no date for the phase 3 readout and no timetable for the phase 1b/2 trial. It lists the company's need for additional capital among its forward-looking topics, and the revolver is the only financing it describes in this 8-K. The loan matures April 21, 2031, and the filing gives no repayment schedule before then.

Report an error

Companies in this story

HURATuHURA Biosciences, Inc.NASDAQ · United StatesOpen the starter desk